The results were not validated in human participants or human kidney samples, so the work identifies a candidate regulatory mechanism rather than a demonstrated treatment for diabetic kidney disease. Diabetic kidney disease is a complex microvascular complication of diabetes that can progress to end-stage renal disease. The study describes interconnected metabolic, hemodynamic, genetic, oxidative and inflammatory processes as contributors to its development and progression.

High glucose can increase reactive oxygen species, or ROS, in mesangial cells, disturbing the balance between oxidants and antioxidant defenses. Such stress can damage cellular components and promote inflammatory signaling. The mechanisms linking individual transfer RNA-derived fragments, or tRFs, to these responses remain incompletely understood, so the researchers focused on tRF-15:31, a fragment previously reported at reduced levels in mouse mesangial cells treated with transforming growth factor beta 1.

To establish the mouse model, investigators used eight-week-old male C57BL/6J mice and assigned them to four groups with five animals per group: untreated controls, mice given streptozotocin, or STZ; STZ plus tRF-15:31; and STZ plus a negative-control RNA. Diabetic kidney disease was established by administering STZ at 50 mg/kg intraperitoneally for five consecutive days. At 12 weeks of age, the researchers confirmed that the model had developed, then delivered either tRF-15:31 or the negative control through a single tail-vein injection of 1 × 10^12 adeno-associated viral particles.

Kidneys and blood were collected at 20 weeks. This design tested the fragment in an intact animal model, but the small group size and use of only one sex and one strain limit how broadly the result can be generalized. In the untreated and STZ comparison, the diabetic mice had more 24-hour urinary protein and higher serum creatinine, two measured indicators of kidney function.

Periodic acid-Schiff staining showed greater glycogen accumulation in their glomeruli, while immunohistochemical analysis found increased tumor necrosis factor alpha, or TNF-α, and interleukin 6, or IL-6. Kidney tissue from STZ-treated mice also contained more malondialdehyde, a lipid-peroxidation product used as an oxidative-stress marker, and less glutathione, or GSH, an antioxidant. TNF-α, IL-6 and monocyte chemoattractant protein 1, or MCP-1, were elevated at the RNA or protein level, while glutathione peroxidase 4, or GPX4, was reduced.

Corresponding changes appeared in cultured mesangial cells maintained under high-glucose conditions. A mannitol control produced no significant changes in the tested inflammatory and oxidative-stress indicators, indicating that high osmolarity alone did not account for those effects. Both kidney tissue and high-glucose-treated cells had significantly lower tRF-15:31 expression.

Overexpressing tRF-15:31 in the diabetic mice produced a pattern of improvement across several outcomes. Compared with STZ-plus-negative-control animals, the treated mice had lower serum creatinine and less 24-hour urinary protein, while blood glucose did not differ significantly. Glomerular glycogen accumulation was reduced in periodic acid-Schiff-stained sections, and renal TNF-α and IL-6 staining was diminished.

The experimental group also had lower TNF-α and IL-6 messenger RNA, lower TNF-α and MCP-1 protein, and higher GPX4 protein. Serum IL-6 and TNF-α concentrations and renal MDA levels fell, whereas renal GSH rose. These are measured changes in an experimental mouse model; they do not by themselves establish that the RNA prevents kidney failure in people with diabetes.

The same broad effects were reproduced in cultured mouse mesangial cells. Investigators introduced a tRF-15:31 mimic into cells exposed to high glucose and confirmed its increased expression by reverse-transcription quantitative PCR. Compared with high-glucose cells receiving the negative control, cells receiving tRF-15:31 had lower TNF-α and IL-6 messenger RNA and lower concentrations of both cytokines in the culture supernatant.

Their MDA and ROS levels declined, GSH levels increased, TNF-α and MCP-1 protein levels fell, and GPX4 protein rose. The parallel findings in the mouse model and cell culture support a biological role for tRF-15:31 in suppressing the oxidative-stress and inflammatory response of mesangial cells under experimental high-glucose conditions. They do not show that the fragment acts identically in human mesangial cells or in the many other cell types present in a diabetic kidney.

Mechanistic experiments pointed to AATF as an important intermediary. AATF messenger RNA and protein were increased in STZ-treated mouse kidneys and in high-glucose-treated mesangial cells, but both were lower after tRF-15:31 was increased. A reciprocal test supported a functional relationship: co-transfecting cells with the tRF-15:31 mimic and an AATF expression plasmid weakened the fragment’s effects on TNF-α, IL-6, MCP-1 and GPX4.

In the other direction, knocking down AATF with small interfering RNA in high-glucose-treated cells reduced TNF-α and IL-6 messenger RNA, lowered TNF-α and MCP-1 protein, increased GPX4 protein, and reduced MDA and cytokine concentrations while preserving more GSH. The researchers then investigated how tRF-15:31 might reduce AATF expression. A computational prediction identified SFRS1 as a possible RNA-binding protein shared by tRF-15:31 and AATF, including a predicted “UGGA” binding site.

RNA immunoprecipitation showed that SFRS1-associated material contained tRF-15:31, while co-immunoprecipitation demonstrated an association between SFRS1 and AATF protein. These complementary assays support physical associations under the tested laboratory conditions, although they do not reveal the precise molecular contact. Knocking down SFRS1 reduced the stability of AATF messenger RNA in an actinomycin D transcription-block experiment.

Increasing tRF-15:31 also shortened AATF messenger RNA stability relative to the negative-control RNA. The proposed mechanism is therefore that tRF-15:31 associates with SFRS1, promotes loss of AATF messenger RNA stability, lowers AATF expression and thereby reduces oxidative stress and inflammatory signaling in mesangial cells. The study has important boundaries.

All in vivo findings came from an STZ-induced mouse model, and all in vitro experiments used a mouse mesangial-cell line, designated SV40-MES 13, under high-glucose conditions. The animal experiments included five mice per group, and the cell experiments were performed in triplicate according to the figure descriptions. The authors emphasize that diabetic kidney disease is a multifactorial disease, so the tRF-15:31–SFRS1–AATF relationship should be viewed as one component of a broader network of metabolic, inflammatory and oxidative pathways.

The evidence supports further investigation of the pathway’s biological significance, while its relevance to human diabetic kidney disease remains to be established.

Subject of Research: Experimental regulation of diabetic kidney injury by tRF-15:31 through SFRS1 and AATF

Article Title: tRF‐15:31‐Arg‐CCT‐3‐1 Improves Diabetic Kidney Disease by Reducing AATF and Alleviating Mesangial Cell Oxidative Stress and Inflammation

Article References: Ning, B., Huang, C., Liu, X., Qiao, Y., Ji, J., Shi, H., Qu, G., Zhao, Y., Gan, W., & Zhang, A. (2026). tRF‐15:31‐Arg‐CCT‐3‐1 Improves Diabetic Kidney Disease by Reducing AATF and Alleviating Mesangial Cell Oxidative Stress and Inflammation. Immunity, Inflammation and Disease, 14(10), Article e70561. https://doi.org/10.1002/iid3.70561

Image Credits: AI Generated

DOI: 10.1002/iid3.70561

Keywords: diabetic kidney disease, tRF-15:31, small non-coding RNA, mesangial cells, oxidative stress, inflammation, AATF, SFRS1, mouse model, kidney injury, Improves, Diabetic

Conventional antioxidant approaches have several limitations, according to the review, including modest antioxidant capacity, poor stability in vivo, low bioavailability and inefficient mitochondrial targeting. Nanotechnology is presented as a way to address these constraints by designing systems that accumulate at injured kidney sites, selectively recognize tubular cells and localize to mitochondria. The organ-to-subcellular targeting strategy is intended to concentrate treatment in the locations where mitochondrial oxidative stress is relevant to acute kidney injury, rather than relying only on the intrinsic antioxidant activity of a compound.

The review categorizes mitochondria-targeted antioxidant nanomedicines by their material type, design principles, mechanisms of action and therapeutic performance. Across these categories, the proposed functions include efficient removal of excessive reactive oxygen species and restoration of mitochondrial function. These systems are described as tools for improving delivery from the whole organ to tubular cells and then to the subcellular level, with the aim of developing safe and effective targeted nanotherapies for acute kidney injury.

The authors also identify major barriers to clinical translation and discuss the conditions required for moving from experimental nanosystems toward clinical use. The article is a review rather than a report of a new treatment trial: it summarizes a research framework and evaluates emerging mitochondria-directed antioxidant nanomedicines, rather than demonstrating clinical benefit in people with acute kidney injury. Its central conclusion is that nanomedicine design may help overcome the delivery and stability limitations of conventional antioxidants, while safety, effectiveness and practical translation remain central requirements for future development.

Subject of Research: Mitochondria-targeted antioxidant nanomedicines for acute kidney injury

Article Title: Nanomedicines targeting mitochondrial oxidative stress for the treatment of acute kidney injury

Article References: Li, T., Xie, T., Chen, J., Sui, X., Xu, Y., Zhang, A., & Chen, J. (2026). Nanomedicines targeting mitochondrial oxidative stress for the treatment of acute kidney injury. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09010-3

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09010-3

Keywords: acute kidney injury, nanomedicine, mitochondrial oxidative stress, reactive oxygen species, targeted drug delivery, mitochondria, kidney injury, antioxidant nanoparticles, clinical translation, Nanomedicines, targeting, mitochondrial

The discovery cohort included 38 bulk RNA-sequencing samples from male C57BL/6J mice divided among four groups: controls on standard chow, high-fat-diet controls, diabetic mice and diabetic mice treated with insulin glargine. Diabetes was induced using six to eight weeks of a high-fat diet containing 60% of calories from fat, followed by five daily injections of streptozotocin. A mouse was classified as diabetic when random blood glucose exceeded 16.7 mmol/L, or 300 mg/dL, on three consecutive measurements. Control and high-fat-diet groups were sampled at all six biweekly intervals, diabetic mice were represented at four intervals after model establishment and RNA quality control, and insulin-treated mice at three intervals because treatment began after the first sampling.

Principal component analysis, used descriptively, separated control from diabetic heart samples as the diabetic group shifted over time, while high-fat-diet samples occupied an intermediate position and insulin-treated samples fell between the control and diabetic clusters. The separation was more pronounced in the kidney, where diabetic samples showed a greater distance from controls. Differential expression analysis, using thresholds of more than a twofold change and an adjusted P value below 0.05, likewise produced more changes in kidney than in heart across the major contrasts. The diabetes-versus-control comparison contained the largest set of kidney-specific changes, and gene ontology enrichment linked those changes to antigen processing and presentation, inflammatory response and leukocyte activation, with false discovery rates below 0.05.

Regression-based maSigPro analysis was then used to identify genes with significant time-dependent profiles. Its thresholds were a Q value below 0.3 and an R-squared value above 0.6, applied as an exploratory screen because the discovery RNA-sequencing cohort included only one animal per group per time point. The kidney yielded 74 unique core time-dependent genes retained across the major renal contrasts. Hierarchical clustering divided them into four groups. The largest contained immune and antigen-presentation genes, including Cxcl10, Icam1, B2m, H2-K1 and H2-D1, while another included metabolic genes such as Mogat2 and Enpp2. Trajectory plots indicated that several inflammatory transcripts rose early in diabetes and later declined. Insulin altered these trajectories during selected intervals, while protein-interaction analysis placed H2-D1, H2-K1, B2m and Cxcl10 at the center of the principal kidney network.

The cardiac response was smaller and followed a different functional pattern. Twenty-two time-dependent cardiac genes were enriched in both immune pathways and metabolic processes. Significant immune terms included leukocyte-mediated cytotoxicity and T-cell-mediated cytotoxicity, with Prf1, Gzmb, Fas and Cd8a among the contributing genes. Metabolic pathways included fatty-acid derivative biosynthesis, while Hmgcs2, Gcdh and Scd1 represented ketogenesis, fatty-acid oxidation and lipid desaturation. The contrast between organs was therefore not simply one of overall disease severity: kidney trajectories were dominated by immunological remodeling, whereas the heart combined immune activation with prominent metabolic adaptation. The six-visit window covered roughly 10 weeks of early-to-intermediate disease in the high-fat-diet and streptozotocin model, not the full course of human cardiorenal disease.

To examine cellular heterogeneity, the researchers analyzed a separate public single-cell RNA-sequencing dataset comprising 16 mouse kidneys from control, diabetic kidney disease and SGLT2 inhibitor treatment groups. After quality control, 18 renal cell types were resolved, including proximal convoluted and straight tubules, injured proximal tubule cells, podocytes, endothelial cells, fibroblasts and immune cells. Enpp2 expression was significantly higher in injured proximal tubule cells from diabetic kidneys than from controls, with a reported P value below 0.001. SGLT2 inhibitor treatment was associated with lower Enpp2 expression in that population. In contrast, the MHC class I transcripts H2-K1 and H2-D1 were lower in immune cells from diabetic kidneys, although comparisons between diabetic and treated kidneys were not uniformly significant for these two genes.

Inferred cell-cell communication networks suggested stronger signaling involving injured proximal tubule cells in diabetic kidneys and reduced interactions associated with fibroblasts, with some of these patterns shifted in the SGLT2 inhibitor group. An overlap analysis also connected the 74 time-dependent bulk kidney genes with cell-type-specific differentially expressed genes; H2-K1 and Plin2 were altered in both datasets. The parallel observations involving two different treatments are hypothesis-generating because insulin and SGLT2 inhibition came from separate cohorts with different designs. The single-cell analysis therefore helped resolve where selected transcripts were expressed, but it could not establish that the drugs had equivalent effects or support a direct ranking of therapeutic efficacy.

Independent quantitative PCR used three mice per group at time points two, three and four. In the heart, Mogat2 and Hmgcs2 showed time-dependent variation: Mogat2 increased in high-fat-diet and diabetic mice at the second time point, while insulin partially attenuated the initial increase and was followed by a later rise and a sharp drop at the fourth point. Hmgcs2 was elevated in diabetic mice from the second time point and followed a different pattern under insulin. Kidney immune markers Cxcl10, H2-D1 and H2-K1 increased significantly in diabetic mice at the second and third time points, with P values below 0.0001, before declining at the fourth. Insulin suppressed these markers during selected intervals. By contrast, Enpp2 remained stable early and rose significantly in diabetic mice at the fourth time point, while Icam1 and Plin2 stayed elevated across the assessed periods.

Protein-level measurements broadly supported selected RNA findings. Immunohistochemical H-scores for ENPP2, ICAM1 and PLIN2 were quantified across 15 randomly selected fields per group by observers blinded to treatment identity. ENPP2 was mainly localized to injured proximal tubular epithelial cells in diabetic kidneys, and insulin markedly reduced this signal. PLIN2 and ICAM1 staining increased in diabetic kidneys, and insulin significantly attenuated both elevations. Histological examination with hematoxylin and eosin and periodic acid-Schiff staining found glomerular and tubular alterations in diabetic kidneys, whereas insulin-treated kidneys more closely resembled controls. The results support a sequence in which early immune activation is followed by later lipid- and adhesion-related remodeling, with systemic glycemic control modifying parts of that sequence. The study does not establish that ENPP2 or PLIN2 directly causes injury, and it was not designed to test treatment benefit in humans.

Several limitations constrain how far the findings can be generalized. The time-series RNA-sequencing phase had one animal per group per time point, making it a discovery screen rather than a definitive population-level trajectory study, and only male mice were included. Although qPCR and immunohistochemistry provided independent validation for selected kidney markers and cardiac transcripts, cardiac proteins and cardiac histology were not assessed in the same way. The sampling window also ended before advanced disease, and no paired functional measures of cardiac or renal performance were reported. Larger studies including both sexes, direct testing of ENPP2 and PLIN2, and functional outcomes would be needed to determine whether the observed modules are causal or clinically predictive. For now, the study offers a time-ordered working model in which the diabetic kidney changes earlier than the heart, early immune activity gives way to structural and lipid-related programs, and insulin is associated with partial rather than complete modulation of selected molecular trajectories.

Subject of Research: Longitudinal transcriptomic differences between diabetic kidney and heart tissue in mice

Article Title: Integrated time-series multi-omics reveals temporal reprogramming and inter-organ divergence in diabetic cardiorenal syndrome

Article References: Gao, S.-S., Wan, G., Wang, Q., An, J., Yang, Q., Liu, C., & Cai, Y. (2026). Integrated time-series multi-omics reveals temporal reprogramming and inter-organ divergence in diabetic cardiorenal syndrome. Frontiers in Endocrinology, 17, Article 1950040. https://doi.org/10.3389/fendo.2026.1950040

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1950040

Keywords: diabetic cardiorenal syndrome, time-series RNA sequencing, single-cell transcriptomics, kidney injury, heart remodeling, ENPP2, PLIN2, ICAM1, insulin treatment, mouse model, Integrated, time-series

ANCA-associated glomerulonephritis is one of the most serious manifestations of ANCA-associated vasculitis, a group of autoimmune conditions in which the body produces antibodies against proteins normally found in neutrophils, the rapidly responding white blood cells that form the first line of defense against infection. When these autoantibodies bind neutrophils, they can push the cells into a destructive state in which they attack the small blood vessels of the kidney’s filtering units, the glomeruli. The resulting inflammation destroys kidney tissue and can progress rapidly to organ failure. Although treatment options have improved in recent years, current therapies rely heavily on broad immunosuppression, which carries risks ranging from serious side effects of prolonged use to outright treatment failure.

Lead author Masayuki Nishide explains why the kidney makes such a valuable window into the autoimmune process. In ANCA-associated glomerulonephritis, the kidneys are frequently involved, which makes the organ an excellent candidate for studying the initial steps of the autoimmune disease sequence. Yet until now, little was known about the order of events that unfold in the earliest phase of the disease, precisely the stage at which an intervention could prevent the most damage.

To reconstruct that sequence, the researchers compared kidney samples from healthy donors with samples from patients with ANCA-associated glomerulonephritis who had not yet received treatment. Using spatial transcriptomics, a cutting-edge technology that reads out gene activity across a tissue while preserving the physical organization of the cells, they studied the progression of the disease in its native cellular context. This approach matters because autoimmune injury is not just about which cells are present but about where they sit relative to one another, and conventional methods that break tissue apart lose exactly that information.

The comparison produced a striking result. Diseased kidneys showed more cellular damage than normal ones, but the changes went deeper than expected. Senior author Atsushi Kumanogoh notes that the team was surprised to find that even in tissue that appeared normal under standard examination, changes could still be detected at the cellular level. The goal, he says, was to investigate exactly how the disease unfolds in the early stage so that it could be stopped before significant damage is done.

The spatial maps revealed a specific pathogenic architecture. Injured proximal tubular epithelial cells, the kidney cells that line the tubules and perform much of the organ’s reabsorptive work, send out signals that attract immune cells, including neutrophils. The accumulating neutrophils cluster around the damaged epithelial cells, forming a local microenvironment the researchers term a neutrophil–epithelial niche. Within this niche, the two cell populations reinforce each other: the injured epithelial cells recruit and stimulate the neutrophils, and the activated neutrophils drive the spread of inflammation through the surrounding kidney tissue. Excessive neutrophil activation emerged as a key feature of early disease, positioning these cells not as innocent bystanders but as central engines of the injury process.

That insight suggested a specific molecular target. Neutrophil activation in this disease depends on Fcγ receptors, the cell-surface proteins that recognize the tail region of antibodies and translate antibody binding into cellular responses. In ANCA-associated glomerulonephritis, stimulation of Fcγ receptors by the disease autoantibodies is integral to the development of the inflammatory process. The researchers therefore engineered modified antibodies designed to minimize stimulation of these receptors, aiming to dampen neutrophil activation without eliminating the cells altogether.

To test the approach, the team replicated the kidney injury in a mouse model of the disease and treated the animals with the modified antibodies. The results were promising: the engineered antibodies successfully reduced kidney injury in the model. By quieting the Fcγ receptor signals that fuel neutrophil activation, the treatment appears to act on the mechanism that drives the earliest phase of the disease, rather than on downstream inflammation that has already caused tissue destruction.

The findings point to a potential new therapeutic strategy aimed at stopping ANCA-associated glomerulonephritis at its earliest stage, before severe kidney damage develops. Because the approach targets a defined step in the disease mechanism, it could in principle offer patients safer treatments with fewer side effects than the broad immunosuppressive regimens used today. The researchers hope that continued development in this area can translate the mouse-model results into clinical benefit, giving patients new options at the stage of disease where intervention matters most.

The study, titled Epitope-diverse autoantibodies induce neutrophil–epithelial niches driving kidney injury in ANCA-associated glomerulonephritis, involved collaboration with Chugai Pharmaceutical Co., Ltd. Several co-authors are employees of and shareholders in the company, and Atsushi Kumanogoh has received grant support from Chugai Pharmaceutical. The work was conducted at the Immunology Frontier Research Center of the University of Osaka using human tissue samples alongside the experimental mouse studies, and it was published in the Journal of Experimental Medicine with the DOI 10.1084/jem.20260506.

Subject of Research: ANCA-associated glomerulonephritis early disease mechanism and modified antibody treatment

Article Title: Curbing the neutrophil surge: New treatment offers hope for autoimmune diseases

Article References: Curbing the neutrophil surge: New treatment offers hope for autoimmune diseases. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: ANCA-associated vasculitis, glomerulonephritis, neutrophils, autoimmune disease, spatial transcriptomics, Fcγ receptors, kidney injury, University of Osaka, Journal of Experimental Medicine, modified antibodies, neutrophil–epithelial niche, immunology

The investigators worked with forty healthy seven-day-old male Shaoxing ducks, a commercially important breed, dividing them into four groups of ten. One group served as untreated controls, one received only Lycium barbarum polysaccharides, or LBPs, at 50 milligrams per kilogram delivered intragastrically, one received cadmium chloride mixed into feed at 50 milligrams per kilogram, and the final group received both. The experiment ran for thirty days under controlled conditions of temperature, humidity, and light. Doses were selected on the basis of previous studies and the team’s own preliminary experiments, and the protocol was approved by the Institutional Animal Care and Use Committee of Yangzhou University.

The consequences of cadmium exposure were quickly apparent. Ducks in the cadmium group lost significant body weight while their kidneys grew heavier relative to body size, a sign of swelling and stress in the organ. Blood chemistry told the same story: levels of creatinine and uric acid, the standard clinical indicators of kidney function, rose sharply. Under the microscope, the damage was striking. Hematoxylin and eosin staining revealed severely disrupted renal architecture, blurred tissue boundaries, atrophied and deformed glomeruli, the kidney’s core filtration units, and hemorrhage in the interstitial spaces. Transmission electron microscopy pushed the view down to the cellular level, exposing nuclear deformation, severe mitochondrial vacuolation, and rupture of the mitochondrial cristae, the folded membranes where cellular energy is produced.

Beneath these visible injuries lay a subtler biochemical sabotage. Using flame atomic absorption spectrometry on digested kidney tissue, the researchers measured the organ’s elemental makeup. Cadmium accumulated dramatically, and as it did, the levels of four essential trace elements, iron, manganese, zinc, and copper, fell. The reason is chemical mimicry. Cadmium shares ionic radius and coordination tendencies with these essential metals, so it can impersonate them in biological systems without performing their functions. The consequences cascade: zinc and copper are components of superoxide dismutase, manganese is the cofactor for the mitochondrial form of that enzyme, and excessive free iron catalyzes the Fenton reaction, generating highly destructive hydroxyl radicals from hydrogen peroxide. Deprived of their raw materials, the antioxidant enzymes falter precisely as the toxic metal floods the system.

The oxidative stress measurements confirmed this collapse. Malondialdehyde, a marker of lipid peroxidation, and hydrogen peroxide rose markedly, while the activities of superoxide dismutase, catalase, and total antioxidant capacity fell, along with the content of glutathione, the cell’s master antioxidant. The team then traced the failure to a master molecular switch. Nrf2 is a transcription factor that, under stress, detaches from its cytoplasmic anchor Keap1, moves into the nucleus, and switches on antioxidant response element-dependent genes. In cadmium-exposed ducks, the protein levels of Nrf2 and its downstream targets, HO-1, NQO1, GCLC, GCLM, and GSR, all dropped. Because GCLC, GCLM, and GSR govern the synthesis and regeneration of glutathione, their suppression crippled the cell’s capacity to manufacture and recycle its most important antioxidant defense.

This is where the wolfberry compound intervened. When ducks received both cadmium and LBP, the pattern reversed. Cadmium burden in the kidney fell, iron, manganese, zinc, and copper levels recovered, the antioxidant enzymes rebounded, and the Nrf2 pathway proteins climbed back toward normal. The researchers attribute the effect to the intrinsic antioxidant, anti-inflammatory, and lipid-lowering properties of LBPs, the major bioactive components of the goji berry, which have been valued in traditional Chinese medicine and are increasingly supported by modern pharmacology. Previous work has shown these polysaccharides acting through multiple signaling pathways with anti-aging, hypoglycemic, immunomodulatory, and neuroprotective effects, and dietary LBP supplementation has already been shown to enhance antioxidant defenses and growth performance in broiler chickens.

But the study’s most novel contribution extends beyond the classic antioxidant story. Cadmium, the team found, triggered a profound disruption of lipid metabolism in the kidney. Total cholesterol and triglyceride levels rose in both serum and kidney tissue, and lipid droplets accumulated visibly under the electron microscope. At the protein level, cadmium upregulated the lipogenic machinery, including FAS, SREBP1, ACC1, ACC2, and PPARγ, the transcription factor that drives adipocyte differentiation and lipid storage. Simultaneously it downregulated the fat-burning side of the ledger: ATGL and HSL, the rate-limiting enzymes that break triglycerides down step by step, along with PPARα, the master regulator of fatty acid oxidation, and CPT2 and LPL, which shuttle fatty acids into mitochondrial beta-oxidation and clear circulating triglyceride-rich lipoproteins respectively. LBP co-treatment corrected both directions of this imbalance, restoring fat breakdown while suppressing excess fat synthesis.

That metabolic rescue rippled into the immune system. The kidney is not merely a filter but an active immune organ, populated by macrophages and T cells that maintain its internal environment. Macrophages polarize into pro-inflammatory M1 cells, marked by iNOS and CD68, or anti-inflammatory M2 cells, marked by Arg1, while T helper cells divide similarly into Th1 and Th2 lineages, tracked by T-bet and GATA3. Cadmium exposure pushed the balance hard toward inflammation: iNOS, CD68, T-bet, and CD4 rose while Arg1 and GATA3 fell, and the inflammatory cytokines IL-18, IL-1β, and TNF-α climbed in kidney tissue. LBP supplementation reversed the polarization markers and substantially lowered all three cytokines. The finding fits into a wider picture in which oxidative stress and disordered lipid metabolism feed chronic inflammation, exhaust immune cells, and ultimately produce immunosuppression, a vicious cycle that the polysaccharide appears to interrupt at multiple points.

The authors are candid about their limits. All results come from phenotypic observations and targeted protein measurements in a live duck model, and without Nrf2 inhibitor or gene-interference experiments the Nrf2 findings indicate correlation rather than proven causality. No transcriptomic or metabolomic analyses were performed, so the global molecular landscape remains unmapped. Even so, the study offers molecular evidence for a natural, widely available feed additive that could protect livestock from heavy metal nephrotoxicity, with implications that reach the human dinner plate, since duck meat and offal enter the food supply chain. As cadmium pollution intensifies with industrialization, a humble berry extract that quiets oxidative stress, restores trace element balance, mends lipid metabolism, and calms inflamed immune tissue is a finding worth watching closely.

Subject of Research: Protective effects of Lycium barbarum polysaccharides against cadmium-induced kidney injury in ducks via the Nrf2 antioxidant pathway

Article Title: Lycium barbarum polysaccharides alleviate cadmium-induced renal injury in ducks by activating the Nrf2-mediated antioxidant defense pathway

Article References: Wang, X., Liu, D., Ma, Y., Zou, H., Tong, X., Zhu, J., Song, R., Zhao, H., & Liu, Z. (2026). Lycium barbarum polysaccharides alleviate cadmium-induced renal injury in ducks by activating the Nrf2-mediated antioxidant defense pathway. Frontiers in Veterinary Science, 13, Article 1998071. https://doi.org/10.3389/fvets.2026.1998071

Image Credits: AI Generated

DOI: 10.3389/fvets.2026.1998071

Keywords: cadmium, nephrotoxicity, Lycium barbarum polysaccharides, Nrf2, oxidative stress, ducks, lipid metabolism, kidney injury, trace elements, antioxidant defense, immune balance, wolfberry

The research, led by Yoshitaka Saito of the Department of Clinical Pharmaceutics and Therapeutics at Hokkaido University of Science together with colleagues at Hokkaido University Hospital, examined 244 patients with thoracic cancers who were treated with cisplatin-based chemotherapy at doses of at least 75 milligrams per square metre of body surface area. Crucially, all of these patients received what is known as the short hydration method, a streamlined fluid regimen that has rapidly become the standard of care for preventing cisplatin-induced nephrotoxicity, the clinical term for chemotherapy-driven kidney injury.

To understand why this finding matters, it helps to grasp how cisplatin attacks the kidney. After intravenous infusion, the drug is filtered by the kidneys and accumulates preferentially in the proximal tubules, the microscopic workhorses responsible for reabsorbing water, salts and nutrients. There, platinum complexes bind to cellular proteins and DNA, triggering oxidative stress, mitochondrial dysfunction and ultimately cell death. The result is a rise in serum creatinine, a waste product that healthy kidneys efficiently clear, and a corresponding drop in creatinine clearance, the standard laboratory measure of how well the kidneys are filtering blood. Clinicians track both values closely during every cycle of cisplatin therapy.

For decades, the answer to this toxicity was aggressive hydration: patients were flooded with litres of saline over many hours, sometimes with forced diuresis using diuretics, to flush the drug through the renal tubules before it could do damage. That approach works, but it is burdensome, often requiring hospital admission for a day or more per cycle. The short hydration method, by contrast, delivers a carefully calibrated volume of fluid over a much shorter window, typically a few hours around the cisplatin infusion, allowing outpatient treatment without sacrificing protection. It represents the most advanced prophylaxis currently available against cisplatin-induced nephrotoxicity.

That is precisely what makes the new result so consequential. Earlier studies had hinted that hypertension might be a risk factor for cisplatin kidney injury, but those analyses were conducted in settings where kidney protection was less rigorous, leaving open the possibility that the association was really a proxy for inadequate hydration rather than a genuine biological vulnerability. By studying a cohort that uniformly received short hydration, the Hokkaido team could test whether hypertension remains a risk factor even under optimal modern prophylaxis. The answer, according to their data, is yes.

Patients were divided into two groups: those with baseline hypertension requiring pharmacological treatment before starting chemotherapy, and a control group without hypertension. Across all treatment cycles, cisplatin-induced nephrotoxicity developed in 18.0 percent of the hypertensive patients, compared with just 6.0 percent of the controls, a threefold difference that reached statistical significance with a P value of 0.008. This comparison served as the study’s primary endpoint, and it was met decisively.

The damage was not limited to a binary yes-or-no outcome. When the researchers examined continuous measures of kidney function, they found that the maximum changes in serum creatinine from baseline were significantly worse in the hypertensive group, with a P value of 0.009, and the maximum changes in creatinine clearance were also notably worse, at P equal to 0.0496. In other words, hypertensive patients did not merely cross a laboratory threshold more often; their kidneys measurably declined further during treatment than those of their normotensive counterparts.

Because this was a retrospective, real-world study rather than a randomised trial, the investigators took careful steps to rule out confounding. They applied propensity score matching, a statistical technique that pairs hypertensive and non-hypertensive patients who share similar baseline characteristics, effectively mimicking the balance of a randomised comparison. The matched analysis reproduced the original findings. The team also repeated the analysis after excluding patients who were concurrently receiving bevacizumab, an anti-cancer antibody known to affect blood pressure and kidney function, and the results remained consistent. Together, these sensitivity analyses strengthen the conclusion that hypertension itself, and not some co-administered drug or demographic imbalance, drives the excess risk.

The biological plausibility of the finding is compelling. Chronic hypertension damages the small vessels of the kidney, causing thickening and narrowing of the arterioles that supply the glomeruli and tubules, a process known as nephrosclerosis. A kidney already operating with compromised blood flow has less physiological reserve to withstand a second insult such as cisplatin. Reduced renal perfusion may also prolong the residence time of the drug within tubular cells, increasing local exposure. In addition, many antihypertensive medications, particularly agents acting on the renin-angiotensin system, alter renal haemodynamics in ways that could interact with the dehydration and electrolyte shifts that accompany cisplatin therapy, although the study did not dissect these mechanisms in detail.

For oncologists and clinical pharmacists, the practical message is clear: baseline hypertension should be treated as a red flag when planning cisplatin-based chemotherapy under short hydration. Patients with treated hypertension may warrant closer monitoring of serum creatinine and creatinine clearance across cycles, earlier nephrology consultation, or consideration of alternative platinum agents such as carboplatin in selected cases. The authors, whose work was funded by JSPS KAKENHI grant number 26K09780 and approved by the Ethical Review Board of Hokkaido University Hospital, note that their findings identify patients with baseline hypertension as being at high risk of developing cisplatin-induced nephrotoxicity even with short hydration. As short hydration continues to spread worldwide as the default kidney-protection strategy, this study serves as a timely reminder that the best protocols still leave vulnerable patients exposed, and that personalised risk assessment, beginning with a simple blood pressure reading taken before the first infusion, may be one of the cheapest and most effective tools in modern cancer care.

Subject of Research: The association between baseline hypertension and cisplatin-induced nephrotoxicity in cancer patients receiving short hydration

Article Title: Association between baseline hypertension and cisplatin-induced nephrotoxicity in patients receiving short hydration

Article References: Saito, Y., Kobayashi, M., Sakamoto, T., Takekuma, Y., Sakakibara-Konishi, J., Shimizu, Y., Kinoshita, I., & Sugawara, M. (2026). Association between baseline hypertension and cisplatin-induced nephrotoxicity in patients receiving short hydration. Scientific Reports. https://doi.org/10.1038/s41598-026-75098-8

Image Credits: AI Generated

DOI: 10.1038/s41598-026-75098-8

Keywords: cisplatin, nephrotoxicity, hypertension, short hydration, kidney injury, chemotherapy, oncology, serum creatinine, creatinine clearance, propensity score matching, thoracic cancer, clinical pharmacy

Diosmin is a naturally occurring flavonoid found predominantly in citrus fruits and has long been used clinically, most famously in formulations for venous disorders such as varicose veins and hemorrhoids. Over the past decade, laboratory studies have accumulated suggesting that the molecule has much broader potential: it has been shown to blunt oxidative damage in models of doxorubicin-induced nephrotoxicity, gentamicin kidney injury, arsenite toxicity, and methotrexate-related organ damage. The catch has always been bioavailability. Diosmin is poorly soluble in water, which limits how much of the compound reaches target tissues when administered in its free form. That pharmacological weakness is precisely what the new study set out to overcome by loading the flavonoid into chitosan nanoparticles, a biocompatible polymer carrier derived from shellfish chitin that is increasingly popular in nanomedicine for its stability, mucoadhesive properties, and ability to sustain drug release.

The experimental design was straightforward but thorough. Sixty female Swiss albino mice were divided into six groups: healthy controls, animals given free diosmin alone, animals given the nanoparticle formulation alone, animals bearing Ehrlich ascites carcinoma without treatment, and two tumor-bearing groups treated with either free diosmin or the nanoparticle version. Both formulations were administered at a dose of 100 milligrams per kilogram per day for twenty days, with or without tumor induction. Ehrlich ascites carcinoma is a widely used preclinical model in which tumor cells proliferate in the peritoneal cavity, causing progressive abdominal swelling, weight gain, and systemic illness that mirrors several features of advanced malignancy in humans, including paraneoplastic organ damage.

The results on tumor burden were unambiguous. Mice receiving the nanoparticle formulation showed significantly lower body weight gain, reduced abdominal circumference, smaller tumor volumes, and lower counts of viable tumor cells than untreated tumor-bearing animals, and the effect was consistently stronger than that achieved with free diosmin. Treated animals also survived longer. According to the authors, the nanoparticle delivery system likely enhanced therapeutic performance through improved stability and sustained-release properties, allowing the flavonoid to remain active in circulation for longer periods and at more effective concentrations than the free compound.

What elevates the study beyond a simple drug-delivery demonstration is its focus on the kidneys. Tumor-bearing mice that received the nanoparticle treatment showed markedly improved renal function markers, including reduced urea and creatinine levels and better-preserved electrolyte balance. This indicates that as tumor progression slowed, the secondary renal injury that accompanies advanced ascites disease was attenuated as well. Histopathological examination of kidney tissue and ultrastructural analysis at the electron microscopy level confirmed that the nanoparticle formulation provided superior structural protection compared with free diosmin, preserving the delicate architecture of the renal tubules and glomeruli far more effectively.

At the molecular level, the researchers traced the protective effect to two interconnected signaling axes. The first is the Nrf2 pathway, the master regulator of cellular antioxidant defense. Under oxidative stress, the transcription factor Nrf2 migrates to the nucleus and switches on genes such as heme oxygenase-1 (HO-1) and NQO1, which manufacture enzymes that neutralize reactive oxygen species. In the treated mice, the Nrf2/HO-1/NQO1 pathway was clearly activated, and this translated into measurable biochemical changes: the activities of superoxide dismutase, catalase, and glutathione peroxidase all increased, levels of reduced glutathione rose, and malondialdehyde, a standard marker of lipid peroxidation and oxidative membrane damage, fell. In other words, the nanoparticle treatment re-armed the kidney’s intrinsic antioxidant machinery at exactly the moment the tumor environment was overwhelming it.

The second axis involves inflammation and programmed cell death. The treatment down-regulated genes controlling inflammatory pathways, including Tgfb1, Nfkb1, and Il6, thereby suppressing the TGF-β, NF-κB, and interleukin-6 signaling cascades that drive both tumor progression and inflammatory kidney damage. At the same time, the formulation shifted the apoptotic balance within kidney tissue: expression of the pro-apoptotic markers Bax and caspase-3 decreased, while the anti-apoptotic protein Bcl-2 increased. This dual suppression of inflammatory signaling and apoptotic execution suggests that the flavonoid protects renal cells not merely by mopping up free radicals but by intervening upstream, at the level of the transcriptional programs that decide whether stressed cells spiral into inflammation and death.

To bolster the experimental findings, the team also performed molecular docking simulations, an in silico technique that models how a small molecule fits into the binding pockets of target proteins. The docking results provided supportive evidence that diosmin can interact with Nrf2, NF-κB, caspase-3, and TGF-β-related molecular targets, the very proteins implicated in the oxidative stress, inflammatory, and apoptotic pathways the study measured. While docking studies are computational and cannot substitute for direct binding experiments, they offer a plausible structural rationale for the pleiotropic effects observed in the animals and help explain why a single flavonoid can touch so many nodes of the damage response network simultaneously.

The study is not without limitations that readers should keep in mind. It was conducted entirely in mice, using a single dose and a fixed treatment window, and the Ehrlich ascites model, although valuable, does not recapitulate every feature of human cancers. The authors note that the datasets used and analyzed in the study are available from the corresponding author on reasonable request, and the work was approved by the ethics committee of the Faculty of Applied Health Sciences Technology at October 6 University in Egypt. Translating these findings into human medicine will require dose-ranging studies, pharmacokinetic profiling of the nanoparticle formulation, and eventually clinical trials in cancer patients at risk of renal injury. Still, the convergence of antitumor efficacy, biochemical protection, histological preservation, and mechanistic coherence makes this one of the more complete preclinical demonstrations of nanodelivered flavonoid therapy to date.

The broader significance lies in what the study says about the future of supportive cancer care. Kidney injury in oncology patients arises from a tangle of causes, including tumor-derived inflammatory mediators, oxidative stress, and the nephrotoxicity of chemotherapeutic agents, and it is associated with worse survival and fewer treatment options. A single agent that simultaneously restrains tumor growth and fortifies kidney tissue against oxidative, inflammatory, and apoptotic damage, delivered through a biocompatible and already clinically familiar polymer carrier, represents an appealing strategy. If subsequent research confirms that diosmin-loaded chitosan nanoparticles behave similarly in larger animal models and in humans, the humble citrus flavonoid long relegated to pharmacy shelves for vein disorders could find a second, far more consequential career in oncology, this time wrapped in nanoparticles and aimed at protecting one of the body’s most vulnerable vital organs.

Subject of Research: Nanoparticle-delivered diosmin as a renoprotective and anticancer therapy in Ehrlich ascites carcinoma-bearing mice

Article Title: Nano-Diosmin mitigates EAC-induced renal injury through Nrf2-mediated antioxidant activation and NF-κB-dependent apoptotic suppression

Article References: Alshammari, A. N., Alfawaz, M. S., Oraby, F., Mohamed, A. M., Elmorsy, E. M., Mohamed, S. S. A., Atta, M. M. F., & El-Raghi, A. A. (2026). Nano-Diosmin mitigates EAC-induced renal injury through Nrf2-mediated antioxidant activation and NF-κB-dependent apoptotic suppression. Medical Oncology, 43(11), Article 317. https://doi.org/10.1007/s12032-026-03387-3

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03387-3

Keywords: diosmin, chitosan nanoparticles, Ehrlich ascites carcinoma, kidney injury, Nrf2, NF-κB, oxidative stress, apoptosis, renoprotection, flavonoids, nanomedicine, Medical Oncology

The study, published in BMC Biology, focuses on sepsis-associated acute kidney injury, or S-AKI, a condition that affects a large proportion of critically ill patients and carries a high risk of progression to chronic kidney disease. The researchers set out to test whether the cholinergic anti-inflammatory pathway, a neuroimmune circuit that dampens inflammation through the alpha-7 nicotinic acetylcholine receptor, could protect the glomerulus, the microscopic ball of capillaries where blood is filtered. What makes the finding remarkable is that this pathway had previously been studied almost exclusively in immune cells and kidney tubules, not in podocytes, the specialized epithelial cells whose interlocking foot processes form the final, finest sieve of the filtration barrier.

Podocytes are among the most architecturally sophisticated cells in the body. Their foot processes wrap around the glomerular capillaries and are bridged by a slit diaphragm, a zipper-like protein junction that contains molecules such as nephrin, podocin, ZO-1, and the actin-bundling protein synaptopodin. When these structures are damaged, as happens during systemic inflammation, the barrier becomes leaky and albumin escapes into the urine, a condition called albuminuria that is both a marker and a driver of further kidney damage. Preserving podocyte architecture during sepsis has therefore been a long-standing goal in nephrology research.

To test their hypothesis, the researchers used a mouse model of sepsis induced by lipopolysaccharide, or LPS, a component of bacterial cell walls that triggers a powerful inflammatory response. When mice were pretreated with GTS-21, a well-characterized agonist of the alpha-7 nicotinic acetylcholine receptor, the results were striking. Kidney function improved, albuminuria was significantly reduced, and transmission electron microscopy revealed that the podocytes’ foot processes retained their normal slender architecture instead of the flattened, fused effacement characteristic of injury. Levels of nephrin, podocin, synaptopodin, and podocalyxin, the molecular pillars of the filtration barrier, were all better maintained in the treated animals, and the organization of ZO-1, a tight-junction scaffolding protein, was partially restored in both glomerular and tubular compartments of the kidney.

A crucial question remained: was the drug acting indirectly, by calming immune cells elsewhere in the body, or was it protecting podocytes themselves? To answer this, the team first mapped where the Chrna7 gene, which encodes the alpha-7 receptor subunit, is expressed within the glomerulus. Using multiplex fluorescent in situ hybridization, they found that Chrna7 signals were broadly distributed across glomerular cells, with partial overlap with podocin, a definitive podocyte marker. They also confirmed that alpha-7 receptor expression could be detected in cultured podocytes, establishing that these cells are equipped to respond to cholinergic signaling directly.

The decisive experiment came with genetics. The researchers generated mice in which Chrna7 was deleted specifically in podocytes, leaving the receptor intact everywhere else. In these knockout animals, the protective effect of GTS-21 was substantially weakened. The drug’s ability to reduce albuminuria was blunted, the preservation of podocyte marker proteins was diminished, and the maintenance of glomerular ZO-1 organization was compromised. This loss-of-function evidence demonstrates that the receptor within podocytes themselves makes a substantial contribution to the glomerular protection conferred by alpha-7 activation, and it establishes podocytes as a direct cellular target of the cholinergic anti-inflammatory pathway.

The team then moved to cultured podocytes to dissect the cellular mechanism. When podocytes were challenged with LPS in vitro, pretreatment with GTS-21 preserved synaptopodin, the actin-associated protein essential for foot process structure, and improved the continuity of ZO-1 staining along cell junctions. Because podocyte injury during inflammation is driven largely by pro-inflammatory signaling cascades inside the cell, the researchers turned to transcriptomic analysis, sequencing the RNA of podocytes under different conditions. The data revealed that alpha-7 activation blunted a key inflammatory program: the NF-kappa-B pathway, a master regulator of the inflammatory response that, when activated, moves its p65 subunit into the nucleus to switch on dozens of inflammatory genes.

Time-course experiments made the suppression of NF-kappa-B signaling visible in real time. In control podocytes exposed to LPS, the p65 subunit rapidly translocated into the nucleus, became phosphorylated, and drove the expression of its target genes. In podocytes pretreated with the alpha-7 agonist, including experiments using a second agonist, PNU-282987, this nuclear translocation was reduced, phosphorylation was diminished, and the expression of downstream target genes fell. Independent quantitative PCR replication confirmed the RNA-sequencing results, strengthening the conclusion that the receptor acts as a brake on one of the central inflammatory circuits that damages podocytes during sepsis.

The implications of the work extend beyond sepsis. The cholinergic anti-inflammatory pathway has attracted intense interest as a therapeutic target for years, with vagus nerve stimulation and alpha-7 receptor agonists being explored for a range of inflammatory diseases. By showing that podocytes carry functional alpha-7 receptors and that activating them preserves the structural integrity of the glomerular filtration barrier, the study reframes the pathway as a multi-compartment strategy: it calms immune cells, protects tubules, and now demonstrably shields the glomerulus itself. For patients with sepsis-associated kidney injury, in whom albuminuria predicts worse outcomes and progression to chronic kidney disease, such a strategy could address both the inflammatory storm and the structural collapse of the kidney’s filter at the same time.

The authors, led by Aobing Yang, Chia-Hsien Wu, and Tsuyoshi Inoue, caution that the findings come from preclinical mouse and cell-culture models, and translating them into clinical practice will require further work, including studies in human tissue and trials of alpha-7 agonists in patients with sepsis. GTS-21, also known as DMXBA, has already been tested in human studies for cognitive disorders, which may ease the path toward repurposing. Still, the study offers a compelling proof of concept that the nervous system’s anti-inflammatory reflex reaches all the way down to the smallest structures of the kidney, and that a single receptor, engaged at the right moment, can hold together the biological sieve on which every one of us depends. As sepsis continues to claim hundreds of thousands of lives each year worldwide, protecting the kidney’s filtration barrier through the body’s own cholinergic circuitry may prove to be one of the most elegant tools yet discovered for that fight.

Subject of Research: Alpha-7 nicotinic acetylcholine receptor activation protects podocytes and glomerular barrier integrity in sepsis-associated acute kidney injury

Article Title: Alpha-7 nicotinic acetylcholine receptor activation preserves podocyte integrity during sepsis-associated kidney injury

Article References: Yang, A., Wu, C.-H., Shimoyama, K., Yamamoto, R., Umene, R., Nakamura, Y., Zhang, Y., & Inoue, T. (2026). Alpha-7 nicotinic acetylcholine receptor activation preserves podocyte integrity during sepsis-associated kidney injury. BMC Biology. https://doi.org/10.1186/s12915-026-02758-6

Image Credits: AI Generated

DOI: 10.1186/s12915-026-02758-6

Keywords: sepsis-associated acute kidney injury, podocytes, alpha-7 nicotinic acetylcholine receptor, GTS-21, cholinergic anti-inflammatory pathway, albuminuria, NF-kappa-B signaling, glomerulus, nephrin, ZO-1, synaptopodin, kidney injury

The research, led by Bin Fang, Fangfang He and Ling Xie of the Department of Nephrology at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, together with colleagues in Wuhan, Xining and Shanghai, focuses on the proximal tubular epithelial cells that line the kidney’s filtering tubules. These cells absorb the bulk of cisplatin from the urine, which is precisely why they bear the brunt of the drug’s toxicity. The team hypothesized that the vulnerability of these cells might be governed not only by which genes are switched on or off, but by how their messenger RNA transcripts are spliced, the molecular editing step that removes introns and stitches exons together into a mature, protein-coding message.

At the center of the story is SLC7A11, the gene encoding the light chain of system xc−, an antiporter that imports cystine into the cell in exchange for glutamate. Cystine is the raw material for glutathione, the cell’s most abundant antioxidant, and glutathione in turn fuels glutathione peroxidase 4, or GPX4, the only enzyme capable of neutralizing the lipid peroxides that accumulate during ferroptosis. When SLC7A11 activity falls, the antioxidant buffer thins, lipid membranes oxidize, and the cell ruptures in the characteristic iron-fueled burn of ferroptosis. Because SLC7A11 sits at this choke point, it has become one of the most intensively studied regulators of ferroptosis in cancer biology and, increasingly, in kidney disease.

What makes the new work unusual is its focus on LUC7L2, a component of the spliceosome previously studied mainly in the context of glucose metabolism in cancer cells. The authors began by showing that LUC7L2 expression rises in models of cisplatin-induced acute kidney injury, both in cultured proximal tubule cells and in animal models. They then manipulated the factor in both directions: silencing it with small interfering RNAs, boosting it with plasmid overexpression, and knocking it down in living animals using adeno-associated virus 9 vectors. The functional readouts were the standard arsenal of ferroptosis assays: cell viability measured by CCK-8, lipid peroxidation tracked through markers such as malondialdehyde and 4-hydroxynonenal, iron accumulation, glutathione levels and GPX4 expression.

The results were consistent across every platform. When LUC7L2 was knocked down, ferroptotic damage receded: cells survived better, lipid peroxidation markers fell, glutathione was preserved and GPX4 held steady. When LUC7L2 was overexpressed, the opposite occurred, with kidney cells sliding more readily into ferroptotic death. In vivo, adeno-associated virus-mediated knockdown of LUC7L2 attenuated renal injury in the cisplatin model, as reflected in the study’s biochemical and histological assessments. In other words, LUC7L2 was not a passive bystander in the injured kidney but an active promoter of the damage.

The mechanistic core of the paper lies in how LUC7L2 acts on SLC7A11. Using exon-specific splicing assays and RNA immunoprecipitation, the researchers showed that the splicing factor binds directly to SLC7A11 pre-messenger RNA and is associated with increased exon skipping. Skipping events that introduce a premature termination codon produce non-productive transcripts, messages that are either degraded or translated into truncated, useless proteins. Under cisplatin stress, LUC7L2 was associated with precisely this kind of non-productive splicing, leaving cells with less functional SLC7A11 protein, diminished cystine import, depleted glutathione and, ultimately, heightened susceptibility to ferroptosis. This is a post-transcriptional layer of control, operating after the gene has been transcribed, that complements rather than duplicates the better-known transcriptional regulation of SLC7A11.

That transcriptional layer, the study shows, belongs to p53, the famous tumor-suppressor protein that cisplatin also activates. The authors describe a dual-pathway mechanism converging on SLC7A11: cisplatin-activated p53 represses transcription of the gene, while LUC7L2 simultaneously corrupts the splicing of whatever pre-messenger RNA is still produced. The two arms of the attack squeeze the antioxidant system from both ends, one throttling the gene’s output at the source and the other degrading the quality of what remains. When the team used pifithrin-alpha, a p53 inhibitor, in their experiments, the transcriptional arm of this squeeze was relieved, underscoring how the two mechanisms operate in parallel rather than in sequence.

To establish that the phenomenon is relevant beyond cell culture and rodents, the researchers reanalyzed public single-cell RNA sequencing datasets to map where LUC7L2 and SLC7A11 are expressed across the many cell types of the kidney, and then validated their findings in human kidney biopsy specimens and urine samples from patients. The single-cell analysis helped define the cell-type-specific expression patterns of the regulatory axis, pointing to the proximal tubule as the site where the LUC7L2–SLC7A11 interaction matters most. The human validation is particularly significant for a field in which promising animal results frequently fail to translate, and it suggests that the splicing factor’s expression could serve as a biomarker of ferroptotic activity in injured kidneys.

The clinical implications run in two directions. As a biomarker, LUC7L2 offers a potential early signal of ferroptotic kidney damage, detectable in urine, that could help clinicians identify patients at risk before blood urea nitrogen and creatinine rise, which are late indicators that appear only after substantial nephron loss has already occurred. As a therapeutic target, the study suggests that damping LUC7L2 activity, or otherwise protecting SLC7A11 splicing, could shield the kidney during cisplatin treatment without necessarily interfering with the drug’s anti-tumor effect, since the protective pathway operates in host tissue rather than in the cancer cells themselves. Ferroptosis inhibitors such as ferrostatin-1 and liproxstatin-1, which the authors used as experimental tools, and antioxidants like N-acetylcysteine represent existing pharmacological handles on the downstream pathway, but a splicing-level intervention would act further upstream and with greater specificity.

There are, of course, caveats. Splicing factors participate in the maturation of thousands of transcripts, and any therapeutic strategy aimed at LUC7L2 would need to account for its broader portfolio of substrates, particularly given its documented role in cancer cell metabolism. The study, which was supported by the National Natural Science Foundation of China and other national and provincial programs, also relies on models of one specific cause of acute kidney injury; whether the same LUC7L2–SLC7A11 axis operates in ischemic, septic or contrast-induced kidney injury remains to be tested. Even so, the work opens a genuinely new chapter in renal protection research. It demonstrates that the fate of a cell under chemotherapy stress can hinge not just on gene expression but on gene editing at the RNA level, and it identifies a concrete, druggable-looking node where ferroptosis, splicing and p53 signaling intersect. For the millions of patients who receive cisplatin each year, that intersection may one day mark the difference between a kidney that recovers and one that does not.

Subject of Research: The role of the splicing factor LUC7L2 in regulating SLC7A11-dependent ferroptosis during cisplatin-induced acute kidney injury

Article Title: LUC7L2 promotes ferroptosis via alternative splicing of SLC7A11 in cisplatin-induced acute kidney injury

Article References: Fang, B., He, F., Xie, L., Yuan, Q., Ye, C., Song, A., Wang, X., Xiong, W., Su, H., Luo, P., Zhang, X., & Zhang, C. (2026). LUC7L2 promotes ferroptosis via alternative splicing of SLC7A11 in cisplatin-induced acute kidney injury. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06411-x

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06411-x

Keywords: LUC7L2, SLC7A11, ferroptosis, acute kidney injury, cisplatin, alternative splicing, p53, GPX4, glutathione, proximal tubular cells, lipid peroxidation, single-cell RNA sequencing

The research team, working at Islamic Azad University’s Central Tehran Branch in collaboration with Shahid Beheshti University, set out to fill a conspicuous gap in the literature. Although Lactobacillus strains have long been associated with protective effects in the female genitourinary tract, their potential to safeguard male reproductive health under active bacterial challenge had never been rigorously tested in a controlled experimental model. The investigators designed a study using a native Iranian probiotic and postbiotic formulation containing three strains: Lactobacillus casei, Lactobacillus rhamnosus, and Lactobacillus helveticus. Their goal was to assess whether these interventions could protect renal integrity, testicular function, and sperm quality in rats experimentally infected with E. coli.

The experimental design was straightforward but comprehensive. Twenty-eight adult male Wistar rats, each weighing between 200 and 250 grams, were acclimatized for one week under controlled conditions of a 12-hour light-dark cycle and an ambient temperature of 23 degrees Celsius. The animals were then divided into four groups: an uninfected control group, a group infected orally with E. coli at a concentration of 10 to the eighth colony-forming units per millilitre for three consecutive days, and two infected groups that subsequently received either the probiotic mixture or the postbiotic preparation by daily oral gavage for 35 days. The postbiotic was prepared by culturing the probiotic powder, centrifuging the suspension, and filtering it through a 0.22-micrometre membrane to obtain cell-free metabolites, ensuring that no living bacteria remained in that treatment arm.

The results were striking. Histopathological examination of kidney tissue revealed that infected rats suffered severe damage, including vacuolar degeneration of tubular cells, extensive haemorrhage, collagen fibre deposition, cellular necrosis, and dense lymphocyte infiltration. Periodic acid–Schiff staining, which highlights basement membrane integrity, confirmed the extent of the injury. In contrast, rats treated with either probiotics or postbiotics showed markedly attenuated pathology, with reduced vacuolization, diminished inflammatory infiltration, and improved glomerular structure. Three blinded pathologists independently scored the sections, achieving an inter-observer agreement coefficient of 0.82, which lends considerable statistical weight to the visual findings.

The testes told a parallel story. Infection caused a significant drop in testicular weight and volume, shrank the diameter of seminiferous tubules from roughly 243 micrometres in controls to 173 micrometres in infected animals, and thinned the germinal epithelium that houses developing sperm cells. The lumen of the tubules, meanwhile, expanded abnormally, a hallmark of germ cell loss. Probiotic and postbiotic supplementation partially reversed these changes: tubule diameter recovered to around 212 to 214 micrometres, germ cell layer thickness rebounded from 149 to roughly 244 to 250 micrometres, and testicular weight climbed back toward control values. Sperm analysis reinforced the pattern, with infected rats showing reduced sperm counts, impaired viability, and abnormal morphology, all of which improved modestly with either treatment.

Blood chemistry provided further evidence of renal protection. Serum urea and creatinine, two classic markers of kidney dysfunction, rose sharply in infected rats compared with controls. Treatment with probiotics or postbiotics significantly lowered both markers relative to the infected group, with creatinine reductions reaching statistical significance at the p less than 0.01 level. Serum potassium followed a similar trend, while sodium concentrations remained unchanged across all groups, indicating that the interventions did not disturb electrolyte homeostasis. These biochemical improvements aligned closely with the histological recovery observed under the microscope.

At the molecular level, the researchers used real-time polymerase chain reaction to quantify the expression of genes governing apoptosis and inflammation. Infection drove a significant upregulation of Bax, a pro-apoptotic gene, alongside elevated expression of the inflammatory cytokines tumour necrosis factor-alpha and interleukin-6 in both kidney and testicular tissue. The anti-apoptotic gene Bcl-2, by contrast, was suppressed. Probiotic and postbiotic treatment flipped this profile: Bax, TNF-alpha, and IL-6 expression fell dramatically compared with infected animals, while Bcl-2 rose significantly. The authors interpret this dual modulation of apoptotic and inflammatory pathways as the central mechanism by which the interventions preserved tissue integrity.

Antioxidant capacity emerged as another critical piece of the puzzle. Total antioxidant capacity in both kidney and testicular tissue was significantly depleted by infection, reflecting the oxidative stress that bacterial pathogens impose on host cells. Supplementation restored these values substantially, with postbiotic-treated animals even showing a modest, though not statistically significant, increase above control levels in kidney tissue. This restorative effect on antioxidant defences likely complements the anti-inflammatory and anti-apoptotic actions, since reactive oxygen species and inflammatory signalling reinforce one another in a vicious cycle that probiotic metabolites appear able to interrupt.

The mechanisms behind these effects are consistent with a growing body of microbiome research. Lactobacillus strains produce lactic acid, hydrogen peroxide, and bacteriocins that directly inhibit pathogenic colonization, while reinforcing epithelial barrier function and modulating toll-like receptor signalling, dendritic cell activity, and cytokine production. Postbiotics, comprising proteins, lipids, short-chain fatty acids, and other fermentation products, deliver many of these benefits without the logistical and safety concerns associated with live microorganisms, which is particularly relevant for immunocompromised patients. The multi-strain approach used here may also amplify protection, as prior studies suggest that combining strains with diverse metabolic and immunomodulatory properties produces synergistic effects.

The authors are careful to note that recovery was partial rather than complete, and that the study was conducted in a rodent model with a defined bacterial challenge rather than the complex, recurrent infections seen in clinical practice. Dose optimization, strain selection, timing of administration, and long-term safety evaluation all remain open questions before such interventions can be recommended for human use. Nevertheless, the findings add meaningful weight to the argument that microbiota-based therapies could serve as adjuncts or alternatives to antibiotics at a moment when antimicrobial resistance is escalating globally. If the protective effects observed in these rats translate to humans, a simple mixture of Lactobacillus strains or their metabolites might one day help men preserve both kidney function and fertility in the face of one of medicine’s most persistent bacterial adversaries.

Subject of Research: Protective effects of Lactobacillus-derived probiotics and postbiotics on renal and reproductive function in E. coli-infected rats

Article Title: Protective Effects of Lactobacillus‐Derived Probiotics and Postbiotics on Renal and Reproductive Function in Escherichia coli–Infected Rats

Article References: Sedghi, S., Keshtmand, Z., & Hosseini, S. (2026). Protective Effects of Lactobacillus ‐Derived Probiotics and Postbiotics on Renal and Reproductive Function in Escherichia coli –Infected Rats. Veterinary Medicine and Science, 12(6), Article e71258. https://doi.org/10.1002/vms3.71258

Image Credits: AI Generated

DOI: 10.1002/vms3.71258

Keywords: probiotics, postbiotics, Lactobacillus, Escherichia coli, urinary tract infection, male infertility, kidney injury, testicular function, sperm quality, oxidative stress, apoptosis, antimicrobial resistance